Wave Life Sciences Ltd (WVE)

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1May 19, 2026 9:49 AM
PR Newswire (US) The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C., May 19, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Wave Life Sciences as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines. AlphaDetect is dedicated to identifying everyone at risk for this progressive, irreversible genetic condition by elevating awareness and removing barriers to detection. The organization will provide free genetic testing for Alpha-1 in their proprietary laboratory, at no cost to insurance or patients. In addition, they provide support from a committed engagement team for healthcare providers. These efforts will increase the availability of Alpha-1 detection tools and support at the practice level while also partnering with healthcare providers to strategically advance protocols and technologies across healthcare systems."We know from conversations with the Alpha-1 community that AATD (Alpha-1 Antitrypsin Deficiency) is highly underdiagnosed and often misdiagnosed. We're proud to support AlphaDetect as an inaugural sponsor and especially excited about this centralized lab for Alpha-1 testing and detection, supported by a team dedicated to the Alpha-1 community," said Christopher Wright, MD, PhD, Chief Medical Officer at Wave Life Sciences. "In addition to genetic testing, AlphaDetect is part of a broader effort to connect people living with Alpha-1 to care, resources, and ongoing research that may potentially have a significant impact on their quality of life and the progression of their disease.""Alpha-1 is a progressive, genetic lung and liver condition where delays in detection may have real, irreversible consequences," said Julie Murray, CEO of AlphaDetect. "The ability to scale proven approaches to identifying at-risk patients, quickly and systematically, can inform timely decisions for those impacted. The support and commitment from Wave Life Sciences are important and appreciated as we continue to advance Alpha-1 detection."Alpha-1 remains significantly underdiagnosed, with more than 90% of affected individuals estimated to be unidentified. It is also the leading known genetic risk factor for COPD and is associated with liver disease in both children and adults. Importantly, detection also provides a point of entry into the Alpha-1 community, opening the door to the comprehensive information, support, and resources needed for the journey ahead."This support builds on Wave Life Science's focus on novel approaches to support the Alpha-1 community and represents an important step forward in how we advance detection," said Scott Santarella, CEO of the Alpha-1 Foundation. "By expanding these efforts through AlphaDetect, we can identify more individuals earlier and deliver on A1F's mission of improving their lives."The latest clinical guidelines recommend testing for Alpha-1 in all individuals with COPD, treatment-resistant asthma, or unexplained liver disease. Yet real-world results fall far short of this. AlphaDetect is committed to closing the gap. Wave Life Science's sponsorship and commitment will help AlphaDetect scale efforts to enhance provider education, broaden detection strategies, and work across the Alpha-1 community to identify individuals with Alpha-1.About AlphaDetect AlphaDetect, founded in 2025, accelerates detection to uncover everyone genetically at risk for Alpha-1. Located in Durham, NC, AlphaDetect will operate as a limited liability company and a non-profit subsidiary of Alpha-1 Foundation, holding tax-exempt status under Section 501(c)3 of the Internal Revenue Code. For more information, visit https://alpha1.org/alphadetect/Contact: Cindy Machles917-453-9760Email: cmachles@alphadetect.orgAbout Wave Life SciencesWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington's disease, as well as several preclinical programs utilizing the company's versatile RNA medicines platform. Driven by the calling to "Reimagine Possible," Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.For more information, visit www.wavelifesciences.comContact: Katie SullivanSenior Director, Corporate Communications617-949-2936MediaRelations @ FoundationThe Alpha-1 Foundation, founded in 1995, is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by the condition worldwide. A1F has invested over $100 million to support Alpha-1 research and programs at 130 institutions in North America, Europe, the Middle East and Australia.For more information, visit?alpha1.orgContact: Jeanne KushnerSenior Director of Communications & Policy877-228-7321jkushner@alpha1.org View original content to download multimedia:https://www.prnewswire.com/news-releases/wave-life-sciences-supports-alphadetect-to-accelerate-detection-of-alpha-1-302776276.htmlSOURCE Alpha-1 Foundation Original: Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1

Wave Life Sciences shares plunge 30% despite encouraging obesity trial resultsMarch 26, 2026 10:12 AM
IH Market News
Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) dropped about 30% on Thursday even after the company released interim Phase 1 data from its INLIGHT study evaluating WVE-007 as a potential treatment for obesity.According to the company, six-month results showed that a single 240 mg dose of WVE-007 produced a placebo-adjusted 14% reduction in visceral fat among otherwise healthy individuals who were overweight or obese. The 240 mg cohort included 32 participants with an average body mass index (BMI) of 32 kg/m², notably lower than the roughly 37 kg/m² BMI typically seen in later-stage obesity trials.Wave said the therapy achieved a 16.5% improvement in the visceral fat-to-muscle ratio compared with baseline. By comparison, weekly semaglutide dosing produced a 12.2% improvement in a separate Phase 2 study that involved participants with higher BMI levels.The treatment also generated a placebo-adjusted 3.3% reduction in waist circumference and a 0.9% drop in body weight after six months. At the same time, lean muscle mass increased by 2.4%.WVE-007 was reported to be generally safe and well tolerated at doses up to 600 mg, with no treatment discontinuations or serious adverse events recorded during the study. Reductions in serum Activin E levels persisted for at least seven months, with maximum decreases reaching as much as 88%, supporting the possibility of dosing once or twice per year.Wave said it plans to launch the Phase 2a portion of the INLIGHT study in the second quarter of 2026. The next stage will enroll participants with higher BMI levels between 35 and 50 kg/m² who also have related health conditions.The company expects the study to demonstrate stronger improvements in body composition and weight loss, potentially supporting development of WVE-007 for obesity as well as conditions such as MASH, type 2 diabetes and cardiovascular disease.The global obesity drug market is currently led by Novo Nordisk and Eli Lilly.Wave Life Sciences stock price

Original: Wave Life Sciences shares plunge 30% despite encouraging obesity trial results

12.14

11.76

Out at $9.75

$9.45 in at $8.30

$8!Wave Life Sciences Ltd - Single 240 Mg Dose of Wve-007 Reduces Visceral Fat by 9.4%

M28 Largest holding they started to trim a little bit. I added the 5.00's core holding.

$WVE

Are these RNA editing indications even necessary with regular RNAI-SIRNA drug pipeline of 450 drugs seems like most of these editing drugs like gene editing are all flops companies not sure about RNA Editing when companies like ALNY and Novartis have the goods to make good old fashion Sirna drugs

$WVE

https://fintel.io/i/m28-capital-management-lp


Top Increases This Quarter

We use the change in the portfolio allocation because this is the most meaningful metric. Changes can be due to trades or changes in share prices.


WVE / Wave Life Sciences Ltd. 5.66 70.07 68.7941 13.2486
TGTX / TG Therapeutics, Inc. 0.16 4.86 4.7756 0.6221
PRQR / ProQR Therapeutics N.V. 1.02 2.70 2.6525 0.6136
SWTX / SpringWorks Therapeutics, Inc. 0.11 3.99 3.9161 0.0293


almost 70% of M28 Capital is in WVE that is lead and advised John Maraganore, PhD. Alnylam Pharmaceuticals. Cambridge, MA. Brook ... M28 Capital Management.

$WVE

Will wait for buyout on my $6.80 average here.

$WVE

RNAI stocks are going to be the biggest driver in biotech in the through 2030 WAVE and PRQR
These could be the next ALNY
450 drugs in the pipeline worldwide for RNAI drugs.

$WVE

Gotta love their business.

If their RNA model works, it could have fantastic results for humanity.

Finally,,,,,,,, "they" will water them all and things will get going. RNA in genetic diseases....

beautiful....

Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

WVE Can't wait for the Phase 1 Obesity indication to commence later this year or early 2025 thats the icing on the cake.

$WVE

can you say breakout?

why claim this afterwards? Pointless

Poetry in Motion!

$WVE

Solid looking for more!

Glad I doubled up last week!

$WVE

wowser there it is

Dystrophin results from a pre-specified analysis of ambulatory boys showed:
Mean absolute muscle content-adjusted dystrophin expression was 9.0% (range: 4.6-13.9%) and mean absolute unadjusted dystrophin expression was 5.5% of normal (range: 3.3-8.3%), as measured by Western Blot.
[...]
89% of ambulatory participants achieved muscle content-adjusted dystrophin levels of at least 5%.

WVE under $7

WVE under $10

one of the singaporean companies that does not look like a scam but rather like singaporean excellence.

WVE under $10

WVE new 52 week high

WVE...BEAUTIFUL WEEKLY

WVE...BIO MONSTER SETTING UP

Big clinical news coming shortly

Company reporting big news next week. Stay tuned!

WVE stretched out this morning!

WAVE LIFE SCIENCES LTD
$5.24 +$0.20 (+3.97%)

WVE is a real stock!

https://stockcharts.com/h-sc/ui?s=WVE